Tandem Diabetes Care, Inc. (TNDM)

Tandem Diabetes Care beat EPS expectations while revenue came in line with consensus, as sales in the second fiscal quarter of 2026 rose 5.8% to roughly $254.6 million (up from about $240.7 million a year ago), results it reported August 6, 2026. EPS of -$0.31 topped the -$0.32 estimate by $0.01, while revenue of $254.6 million was in line with the $255.0 million estimate (-0.2%). Gross profit was about $144.8 million and gross margin printed at roughly 57%, alongside an operating loss of about $13.8 million that translated to an operating margin of -5.4%. Net loss narrowed to roughly $21.2 million, down 59.6% from a net loss of about $52.4 million a year ago. The quarter also included negative operating cash flow of roughly $34.6 million. For the next period, consensus calls for EPS of -$0.26 on revenue of $266.1 million.